GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ABVC BioPharma Inc (NAS:ABVC) » Definitions » Current Ratio

ABVC BioPharma (ABVC BioPharma) Current Ratio : 0.28 (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is ABVC BioPharma Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. ABVC BioPharma's current ratio for the quarter that ended in Dec. 2023 was 0.28.

ABVC BioPharma has a current ratio of 0.28. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If ABVC BioPharma has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for ABVC BioPharma's Current Ratio or its related term are showing as below:

ABVC' s Current Ratio Range Over the Past 10 Years
Min: 0.02   Med: 0.41   Max: 2.71
Current: 0.28

During the past 13 years, ABVC BioPharma's highest Current Ratio was 2.71. The lowest was 0.02. And the median was 0.41.

ABVC's Current Ratio is ranked worse than
93.37% of 1554 companies
in the Biotechnology industry
Industry Median: 3.79 vs ABVC: 0.28

ABVC BioPharma Current Ratio Historical Data

The historical data trend for ABVC BioPharma's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ABVC BioPharma Current Ratio Chart

ABVC BioPharma Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 1.27 2.07 0.54 0.28

ABVC BioPharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.54 0.69 0.37 0.47 0.28

Competitive Comparison of ABVC BioPharma's Current Ratio

For the Biotechnology subindustry, ABVC BioPharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ABVC BioPharma's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ABVC BioPharma's Current Ratio distribution charts can be found below:

* The bar in red indicates where ABVC BioPharma's Current Ratio falls into.



ABVC BioPharma Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

ABVC BioPharma's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=1.657/5.932
=0.28

ABVC BioPharma's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=1.657/5.932
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ABVC BioPharma  (NAS:ABVC) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


ABVC BioPharma Current Ratio Related Terms

Thank you for viewing the detailed overview of ABVC BioPharma's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ABVC BioPharma (ABVC BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
44370 Old Warm Springs Boulevard, Fremont, CA, USA, 94538
ABVC BioPharma Inc is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
Executives
Shuling Jiang director, 10 percent owner 44370 OLD WARM SPRINGS BLVD., FREMONT CA 94538
Shih-chen Tseng director 5F., NO. 41-1, LN. 12, SINDONG ST., SONGSHAN DIST, TAIPEI CITY F5 105065
Yoshinobu Odaira director 4823 DUNDAS STREET, THOMDALE, LONDON X0 N6P 1J1
Norimi Sakamoto director 4823 DUNDAS STREET, THRONDALE, LONDON X0 N6P 1J1
Shin-yu Miao director NO. 25-12, AMLIN RD., XITUN DIST., TAICHUNG CITY F5 407676
Tsung Shann Jiang director, officer: CSO and Director 1197 LA PLURISSIMA PL, FREMONT CA 94539
Eugene Jiang director, officer: Chairman of the Board & CBO 1197 LA PLURISSIMA PL, FREMONT CA 94539
Chang-jen Jiang director 1197 LA PLURISSIMA PL, FREMONT CA 94539
Yen-hsin Chou director 13F. NO. 2, MEISHU E. 8TH ST.,, GUSHAN DIST., KAOHSIUNG CITY F5 804413
Chi-hsin Richard King officer: Chief Scientific Officer 11907 GRANT PLACE, SAINT LOUIS MO 63131
Howard Doong officer: Chief Executive Officer 44370 OLD WARM SPRINGS BLVD., FREMONT CA 94538
Chihliang An officer: Chief Financial Officer 32458 JEAN DR, UNION CITY CA 94587
Tsang Ming Jiang director 1197 LA PURISSIMA PL, FREMONT CA 94539
Shulamit Lazar director, 10 percent owner, officer: President,Secretary,Treasurer 8605 SANTA MONICA BOULEVARD, SUITE 41336, LOS ANGELES CA 90069
Kevin Patrick Stolz officer: CFO & Controller 2701 CAMBRIDGE COURT, SUITE 100, AUBURN HILLS MI 48326